Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Avogaro

Showing results (21-30 of 426) with videos related to

Pageof 43
Sort By:
Acta Diabetologica|December 6, 2012
Achieving glycemic control in patients with type 2 diabetes and renal impairmentAngelo Avogaro, Guntram Schernthaner
Archives of Physiology and Biochemistry|June 19, 2013
Abnormalities of the cardiac stem and progenitor cell compartment in experimental and human diabetesAnna Leonardini, Angelo Avogaro
Expert Opinion on Pharmacotherapy|March 10, 2017
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetesPaola Fioretto, Angelo Avogaro
Cardiovascular Diagnosis and Therapy|November 7, 2015
Mechanisms of ectopic calcification: implications for diabetic vasculopathyAngelo Avogaro, Gian Paolo Fadini
The Lancet. Diabetes & Endocrinology|July 23, 2017
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting SystemGian Paolo Fadini, Angelo Avogaro
Atherosclerosis|March 30, 2010
Exploring interactions among metabolic syndrome traits. Methods and meaningGian Paolo Fadini, Angelo Avogaro
Cardiovascular Research|April 30, 2010
Cell-based methods for ex vivo evaluation of human endothelial biologyGian Paolo Fadini, Angelo Avogaro
Experimental Diabetes Research|May 2, 2012
It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complicationsGian Paolo Fadini, Angelo Avogaro
Cardiovascular Diabetology|February 4, 2018
How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitorsGian Paolo Fadini, Angelo Avogaro
Vascular Pharmacology|June 14, 2011
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1Gian Paolo Fadini, Angelo Avogaro
Pageof 43

Showing results (21-30 of 426) with videos related to

Sort By:
Pageof 43
Acta Diabetologica|December 6, 2012
Achieving glycemic control in patients with type 2 diabetes and renal impairmentAngelo Avogaro, Guntram Schernthaner
Archives of Physiology and Biochemistry|June 19, 2013
Abnormalities of the cardiac stem and progenitor cell compartment in experimental and human diabetesAnna Leonardini, Angelo Avogaro
Expert Opinion on Pharmacotherapy|March 10, 2017
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetesPaola Fioretto, Angelo Avogaro
Cardiovascular Diagnosis and Therapy|November 7, 2015
Mechanisms of ectopic calcification: implications for diabetic vasculopathyAngelo Avogaro, Gian Paolo Fadini
The Lancet. Diabetes & Endocrinology|July 23, 2017
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting SystemGian Paolo Fadini, Angelo Avogaro
Atherosclerosis|March 30, 2010
Exploring interactions among metabolic syndrome traits. Methods and meaningGian Paolo Fadini, Angelo Avogaro
Cardiovascular Research|April 30, 2010
Cell-based methods for ex vivo evaluation of human endothelial biologyGian Paolo Fadini, Angelo Avogaro
Experimental Diabetes Research|May 2, 2012
It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complicationsGian Paolo Fadini, Angelo Avogaro
Cardiovascular Diabetology|February 4, 2018
How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitorsGian Paolo Fadini, Angelo Avogaro
Vascular Pharmacology|June 14, 2011
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1Gian Paolo Fadini, Angelo Avogaro
Pageof 43